44th week of 2013 patent applcation highlights part 43 |
Patent application number | Title | Published |
20130287691 | ANTI-GD2 ANTIBODIES AND METHODS AND USES RELATED THERETO - Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described. | 2013-10-31 |
20130287692 | RIFAMYCIN DERIVATIVES - Disclosed are rifamycin derivatives having antibacterial activities, wherein the compounds have the following general formula: | 2013-10-31 |
20130287693 | NOGO Receptor Binding Protein - The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof. | 2013-10-31 |
20130287694 | ANIMAL MODEL OF ANXIETY AND DEPRESSION - This invention relates generally to animal models of anxiety and depression. Specifically, this invention relates to an in vivo high utility, high-throughput model for screening anxiolytic/antidepressant drugs in fowl chicks with stress vulnerability. This new animal model utilizes an inexpensive avian model, measures spontaneous behaviors in very young animals, and is capable of detecting and/or differentiating a compound's anxiolytic and/or antidepressant effects. This new animal model is especially useful in detecting and/or differentiating a compound's anxiolytic and/or antidepressant effects in treatment-resistant subjects. Animal costs are less than 10% of rodent costs and the assay can be run in a high-throughput mode. | 2013-10-31 |
20130287695 | CHONDROCYTE-LIKE CELL, AND METHOD FOR PRODUCING SAME - Disclosed is a cell which enables the reproduction of a cartilage tissue and has a proliferative ability. Also disclosed is a technique for providing a cell supply source which can be used in a definitive treatment of osteochondrosis deformans. A chondrocyte-like cell which has the same properties as those of a chondrocyte and can proliferate can be produced by selecting a combination of an Myc family gene and/or a Klf family gene and a SOX9 gene and introducing the combination into a somatic cell. The chondrocyte-like cell can be used for a medical purpose of cartilage regeneration. | 2013-10-31 |
20130287696 | POLYETHYLENE GLYCOLATED SUPEROXIDE DISMUTASE MIMETICS - Compounds and methods for utilizing compounds comprising a superoxide dismutase mimetic covalently linked to polyethylene glycol. Methods are also provided for preparing a superoxide dismutase mimetic covalently linked to a polyethylene glycol, the methods comprising reacting an activated polyethylene glycol with a superoxide dismutase mimetic, or alternatively, reacting a superoxide dismutase mimetic with an activated polyethylene glycol. A method is also provided for preventing or treating a disease or disorder in which superoxide anions are implicated, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound comprising a superoxide dismutase mimetic covalently linked to a polyethylene glycol. Methods of determining the safety and efficacy of the compounds are also provided. Methods for determining the safety and efficacy can include methods in lab animals and humans. | 2013-10-31 |
20130287697 | Pharmaceutical microsphere for embolization - A pharmaceutical microparticle for embolization is disclosed, which includes: a thermoresponsive polymer, an enhancer, a contrast agent, and a solvent. The particle size of pharmaceutical microparticle for embolization is 100-750 μm. The pharmaceutical microparticle for embolization of the present invention is an effective drug carrier, and has biodegradable and X-ray imaging properties. | 2013-10-31 |
20130287698 | TREATMENT OF RENAL HYPERTENSION OR CAROTID SINUS SYNDROME WITH ADVENTITIAL PHARMACEUTICAL SYMPATHETIC DENERVATION OR NEUROMODULATION - Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient. | 2013-10-31 |
20130287699 | Luciferin Derivatives from Bicyclic Reactants and Aminothiol Derivatives and Methods of Use Thereof - The present disclosure features a condensation reaction and a luciferin-unmasking reaction that can be carried out under physiological conditions. In general, the condensation reaction involves reacting a bicyclic reactant with an aminothiol derivative, generating a luciferin or luciferin derivative. A luciferin can provide detectable luminescence. A luciferin derivative can be unmasked to provide detectable luminescence in a luciferin-unmasking reaction. The present disclosure provides bicyclic reactants and aminothiol derivatives suitable for use in the condensation reaction. The condensation and luciferin-unmasking reactions find use in a variety of applications, which are also provided. | 2013-10-31 |
20130287700 | COMPOUNDS FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISORDERS ON THE OLFACTORY EPITHELIUM - Subject of the present invention are compounds with high affinity for the Aβ protein, α-synuclein or for Tau-PHF aggregates, which are suitable as preferably fluorescent probes for the in vivo diagnosis of neurodegenerative disorders like e.g. Alzheimer's disease and Parkinson's disease. The compounds are characterized by suitable physicochemical properties (excitation wavelength, emission wavelength, Stokes shift, extinction) as well as a high affinity and selectivity for the target proteins. | 2013-10-31 |
20130287701 | METHOD OF DETECTING RISK OF CANCER - The invention provides an ex vivo method for detecting the risk of cancer in a patient, comprising the step of: (iii) detecting the expression level of the genes identified herein as ELN, RGS-1, SOCS-3, PTGS-2, JUN, ATF-3, CTGF, IGF-2 and RBMS-1, in a sample of genetic material isolated from a patient, wherein the combined expression level indicates the risk of cancer in the patient from whom the sample was isolated. | 2013-10-31 |
20130287702 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER CELLS - A molecular probe for use in detecting, monitoring, and/or imaging cancer cells and/or cancer cell metastasis, migration, dispersal, and/or invasion includes a targeting agent and a detectable moiety. The targeting agent specifically binds to and/or complexes with a proteolytically cleaved extracellular fragment of an immunoglobulin (Ig) superfamily cell adhesion molecule that is expressed by a cancer cell or another cell in the cancer cell microenvironment. | 2013-10-31 |
20130287703 | CORE/SHELL MULTIFUNCTIONAL MAGNETIC NANOPHOSPHOR HAVING CORE/SHELL STRUCTURE AND SYNTHETIC METHOD THEREOF - The present invention relates to a nanophosphor and a synthesis method thereof, and provides a nanophosphor comprising a first compound of Formula 1, wherein the first compound is fluoride-based one which is co-doped with Ce | 2013-10-31 |
20130287704 | ARTICLE AND METHODS FOR ORAL SELF-ADMINISTRATION OF NICOTINE - The invention discloses an article for swaddling in the mouth to deliver pharmacologically active substances, particularly nicotine, in combination with dyes or flavorings, across the buccal membranes when said article is swaddled in the mouth. Advantageously, the article comprises an indicator element at one end protruding from the mouth such that when the article is swaddled in the mouth the indicator element conveys information about the commercial origin of the article or the substances and flavorings delivered thereby. The article comprises a non-edible substantially cylindrical core element, such as a toothpick, and the indicator element may be a bulb, trinket, insignia or other marking. In a preferred embodiment, the invention makes a social statement about the beneficial uses of nicotine. Methods for using the invention to mitigate sensations of nervousness and boredom are also disclosed. | 2013-10-31 |
20130287705 | METHOD OF TREATING MUCOSAL INFLAMMATION - A method of treating mucosal inflammation associated with a pathological condition in a mammal is provided. The method comprises the step of inhibiting 5-HT signaling at a target site in order to block 5-HT7 receptor function. | 2013-10-31 |
20130287706 | STABLE EFFERVESCENT BISPHOSPHONATE FORMULATIONS WITH RAPID SOLUBILIZATION CHARACTERISTICS - A stable effervescent tablet, granule or powder composition free from excipients that may react with an effervescing organic acid component, comprising, an effective amount of a bisphosphonate bone resorption inhibitor, an effervescing organic acid component, an effervescing base component; wherein said composition is free of polyol binders and tableting lubricants; has a loss on drying of 0.25% (m/m) or less; has a complete disintegration time of no more than 180 seconds when placed in 3 to 8 fluid ounces of water at between 5-20° C.; and said bisphosphonate is incorporated as a micronized particle or by spray drying and is completely solubdised in water within 2 minutes without stirring. | 2013-10-31 |
20130287707 | 6a,7,7-TRIMETHYLDECAHYDRO-1,4-METHANOCYCLOPROPA[de]NAPHTHALEN-1-OL - As a novel compound which is excellent in odor quality and has an odor of a very clear and strong woody note, the invention provides a compound represented by the following formula (1): | 2013-10-31 |
20130287708 | NATURAL FORMULATIONS - Provided is an all natural composition including naturally-obtained plant extracts. | 2013-10-31 |
20130287709 | Metal Salt Compositions - Described herein are compositions comprising combinations of metal salts, and methods of preparing and using the same. | 2013-10-31 |
20130287710 | Oral Care Compositions - Oral care compositions comprising a crosslinked polyvinylpyrrolidone complexed with hydrogen peroxide, together with an ethylene oxide-propylene oxide block copolymer. Some embodiments further comprise a calcium abrasive, e.g. calcium pyrophosphate or calcium carbonate, and some may have less than 3% water. | 2013-10-31 |
20130287711 | Oral Compositions and Method for Producing Thereof - Methods of preparing a dentifrice comprising polymer matrix film with a low solubility flavorant therein are disclosed. The methods comprise combining a polymer matrix film that are free of a low solubility flavorant with a dentifrice base comprising a low solubility flavorant and maintaining the combined polymer matrix film with the dentifrice base comprising low solubility flavorant for an amount of time sufficient for an amount of a low solubility flavorant to transfer from the dentifrice base comprising low solubility flavorant to the polymer matrix film Products comprising low solubility flavorant-free polymer matrix film in a dentifrice base comprising low solubility flavorant are also disclosed. | 2013-10-31 |
20130287712 | FOAMING FORMULATIONS INCLUDING SILICONE-BASED POLYURETHANES - Foaming formulations including silicone-based polyurethanes are disclosed. These foaming formulations are useful as cleansing formulations such as used in hand sanitizers. The foaming formulations provide improved aesthetic properties and foaming appearance, while maintaining high antimicrobial capacity. | 2013-10-31 |
20130287713 | HIGH LUBRICATION SHAVING AID - A shaving aid composition is provided that includes an organic polyhalogenic agent that both promotes post application foaming and increases lubricity. The shaving aid is optionally used to deliver one or more therapeutics to the skin of a subject and is therefore operable to prevent or treat a skin condition. | 2013-10-31 |
20130287714 | COSMETIC AND/OR DERMATOLOGICAL PREPARATIONS CONTAINING SNOW ALGAE EXTRACT - The present invention describes cosmetic or dermatological preparations which contain snow algae extracts and one or several substances which are suitable for skin protection. | 2013-10-31 |
20130287715 | USE OF NATURAL ACTIVE SUBSTANCES IN COSMETIC OR THERAPEUTIC COMPOSITIONS - The invention relates to cosmetic or therapeutic compositions that contain hydrolysed yeast proteins as an active ingredient, to the use of said cosmetic or therapeutic compositions, and to a method for cosmetic treatment. | 2013-10-31 |
20130287716 | 7-ACYLOXYCHROMEN-4-ONE DERIVATIVES AND THE USE THEREOF AS SELF-TANNING SUBSTANCES - The present invention relates to chromen-4-one derivatives of the formula (I), to the use thereof as self-tanning substance or for increasing melanin synthesis, improving melanin transport and/or improving the distribution of melanin in suprabasal layers, and to preparations comprising these chromen-4-one derivatives. | 2013-10-31 |
20130287717 | METHOD FOR IMPROVING SKIN APPEARANCE AND REDUCING HAIR LOSS - A method for improving skin appearance and/or reducing hair loss in a subject is provided. The method comprises administrating to the subject an effective amount of peripheral monocytes, wherein the peripheral monocytes are induced by granulocyte colony stimulating factor (GCSF) or a combination of GCSF and an interleukin relative to GCSF. | 2013-10-31 |
20130287718 | SKIN EXTERNAL PREPARATION AND METHOD OF PRODUCING SAME - A skin external preparation containing an ascorbic acid-2-phosphate derivative is characterized in that only a sodium ascorbic acid-2-phosphate-6-palmitate is formulated as the ascorbic acid-2-phosphate derivative, and the skin preparation further includes at least one betaine-type amphoteric surfactant selected from the group consisting of compounds represented by the following general formula (1) or (2) (wherein R | 2013-10-31 |
20130287719 | HAIR COLOURING COMPOSITION - Present invention relates to a dyeing composition for hair with improved dyeing and conditioning properties of hair. The object of the present invention an aqueous composition for dyeing hair based on at least one oxidizing agent and at least one hair dye and comprising a polyhydroxy carboxylic acid as a chelating agent. The compositions of the present invention are aqueous compositions and comprise at least 40%, more preferably 50%, most preferably 60% and in particular 70% by weight water, calculated to total of the composition. | 2013-10-31 |
20130287720 | PROCESS FOR PREPARING VESICLE COMPOSITION - The present invention relates to a process for preparing a vesicle composition having a continuous phase constituted of an aqueous phase, including: melting an oil phase at a temperature of equal to or higher than a melting point of the oil phase, the oil phase containing following components (A) to (D): component (A) straight chain fatty acid having 14 to 24 carbon atoms; component (B) branched fatty acid having 14 to 24 carbon atoms and having a certain structure; component (C) tertiary amine compound; and component (D) organic acid having 1 to 8 carbon atom(s), mass ratio of the component (A) and the component (B) being: (A)/(B)=70/30 to 40/60, and adding the melted oil phase to the aqueous phase while mixing thereof. | 2013-10-31 |
20130287721 | METHOD FOR COUNTERACTING AMMONIA MALODOR - The present invention relates to a method for counteracting ammonia malodor comprising indentifying PRMs capable of elevating the lateralization threshold of ammonia and using such ingredients in a perfume applied to surfaces or spaces exposed to ammonia or to consumer product bases comprising ammonia. | 2013-10-31 |
20130287722 | METHOD FOR PRODUCING AN AQUEOUS STABLE CHLORINE DIOXIDE SOLUTION - The invention relates to a method for producing an ultrapure, aqueous, long-term- and storage-stable, and thus transportable, chlorine dioxide solution, comprising the steps of: providing chlorite, providing peroxodisulfate, and combining chlorite and peroxodisulfate in an aqueous system and in a molar ratio of peroxodisulfate to chlorite [S | 2013-10-31 |
20130287723 | INORGANIC GEL FOR CONTROLLED RELEASING OF FRAGRANCE AND DISINFECTANT - A gel composition for air freshening or disinfecting, comprising a silicon alkoxide or colloidal silica, a volatile or gaseous fragrance and/or disinfectant, water, an acid or base catalyst, a water-soluble solvent, and optionally other volatile components and additives, and a method for preparing the same. The gel can be transparent or colored, has a homogeneous texture and a soft to rigid structure, and contains volatile or gaseous components from 0 vol % to 85 vol % for scented materials (fragrance and oils) and/or 0-8000 ppm of disinfectant, which are released at a steady rate under ambient conditions, controlled by the shape and opening of the gel container. Botanicals or plastic decorations may be added into the gel to improve its aesthetic appeal. The preparation method is easier and requires less energy consumption and the gel is used as an air freshener or disinfectant. | 2013-10-31 |
20130287724 | ANTI-ADHERENT FORMULATION INCLUDING AN ANIONIC OR NONIONIC POLYMER - Liquid formulations having anti-adherent properties are disclosed herein. The liquid anti-adherent formulation described herein acts to prevent the adherence of menses and/or fecal material to the skin in the labial and perianal regions during and after menstruation or defecation, respectively. The liquid anti-adherent formulation contains a carrier, a polymer selected from an anionic polymer, nonionic polymer, and combinations thereof. Anti-adherent formulation was found to be effective if a menses leave-on percentage as defined within the Menses Leave-On Percentage Test method described herein of less than 7.2% after two insults. | 2013-10-31 |
20130287725 | BIOCOMPATIBLE POLYMERS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM - A process for treating fibroses including administering a therapeutically effective amount of a pharmaceutical composition which includes at least one biocompatible polymer of the following general formula (I): A | 2013-10-31 |
20130287726 | COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND METHODS OF SELECTION THEREOF - A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed. | 2013-10-31 |
20130287727 | Psyllid Attractants and Their Uses - The present specification discloses psyllid attractants, compositions comprising such attractants, lures, traps and other devices using such attractants, methods and uses to attract, capture and/or kill psyllids using such attractants, compositions and/or lures, traps and/or other devices, and methods and uses for monitoring a psyllid population using such attractants, compositions and/or lures, traps and/or other devices. | 2013-10-31 |
20130287728 | Compositions and Methods for Treating Progressive Myocardial Injury Due to A Vascular Insufficiency - The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury-due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional active agent. The method treats ongoing vascular insufficiency affecting coronary circulation by (i) stimulating neoangiogenesis in a peri-infarct border zone, thereby improving myocardial perfusion; and, (ii) through a paracrine effect, preventing apoptosis of cardiomyocytes in the peri-infarct border zone. The neoangiogenesis and paracrine-mediated reduction of apoptosis reduces progressive myocardial cell loss, which leads to improvement in cardiac function and a reduction of risk of major adverse cardiovascular events. | 2013-10-31 |
20130287729 | ANTIGEN-SPECIFIC, TOLERANCE-INDUCING MICROPARTICLES AND USES THEREOF - The present invention provides antigen-specific, tolerance-inducing microparticles for the targeted delivery of therapeutic agents to immune cells. In addition, the present invention allows for sustained release of therapeutic agents for a prolonged period of time. Also provided are therapeutic uses of the present invention for the prevention and/or treatment of immune diseases and autoimmune disorders. In a specific embodiment, the present invention provides treatment for type 1 diabetes. | 2013-10-31 |
20130287730 | PIPERAZINE-PIPERIDINE COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The invention provides compounds of formula (I): | 2013-10-31 |
20130287731 | HEPATITIS C VIRUS INHIBITORS - The invention provides compounds of formulas (I) or (II): | 2013-10-31 |
20130287732 | Neuroprotection in Demyelinating Diseases - Methods of treating neurological disorders, e.g., those characterized by demyelination and/or axonal loss (e.g., MS), are provided. The methods comprise administration of a therapeutically effective amount of at least one compound of Formula I: | 2013-10-31 |
20130287733 | INTERFERON ALPHA MUTANT AND ITS POLYETHYLENE GLYCOL DERIVATIVE - IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein a polyethylene glycol moiety is covalently bound to the free Cys residue of an IFN-alpha mutant. The preparation methods of PEG derivatives of IFN-alpha mutants and medical compositions comprising the derivatives are also provided. The test results showed that the IFN-alpha mutants of the present invention are ready to prepare and have high activity; their polyethylene glycol derivatives have extended lifetime in the body and low clearance rate. | 2013-10-31 |
20130287734 | LIQUID FORMULATIONS OF LONG ACTING INTERFERON ALPHA CONJUGATE - Disclosed is a liquid formulation in which a long-acting INFα conjugate that has improved in vivo duration and stability can be stored stably for a long period of time. It comprises a stabilizer comprising a buffer, a sugar alcohol, a non-ionic surfactant and an isotonic agent. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting INFα conjugates. | 2013-10-31 |
20130287735 | HIGH POROSITY MATERIALS, SCAFFOLDS, AND METHOD OF MAKING - Materials and methods for preparing three dimensional scaffolds are described. The materials, as improved high internal phase emulsions (HIPES), and the polymerization thereof may be suitable for injection prior to curing and when in an injectable form may be for site-directed in vivo use, curing after injection. In addition, said materials before curing may be engineered as a tissue substitution or enhancement and/or to include cell encapsulation. Said materials described herein form a monolith after curing and are biodegradable and porous after curing. Said materials are made from starting molecules using a process that does not rely on toxic solvents or monomers. Making of said materials to form the emulsion take advantage of one or more surfactants for HIPE stability. In addition, said materials cure at temperatures appropriate for use in an in vivo or in situ environment. | 2013-10-31 |
20130287736 | GENE THERAPY FOR NEURODEGENERATIVE DISORDERS - Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed. | 2013-10-31 |
20130287737 | Poxviral Oncolytic Vectors - The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer. | 2013-10-31 |
20130287738 | DISEASE-ASSOCIATED PROTEIN - Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions. | 2013-10-31 |
20130287739 | SERCA2 THERAPEUTIC COMPOSITIONS AND METHODS OF USE - The present invention provides methods for treating pulmonary hypertension in a subject by delivering a therapeutic adeno-associated virus (AAV)-SERCA2 composition to a subject in need thereof. | 2013-10-31 |
20130287740 | COMPOSITIONS FOR PREPARING A COFFEE BEVERAGE COMPRISING HYDROLYSED CHLOROGENIC ACID - The invention relates to compositions for preparing a beverage, the compositions comprise a microorganism and/or an enzyme capable of hydrolysing chlorogenic acids of a coffee extract to phenolic acids. When a beverage prepared with the compositions of the invention is consumed chlorogenic acids present in coffee extract is hydrolysed to improve antioxidant and/or anti-inflammatory properties compared to a similar conventional beverage. | 2013-10-31 |
20130287741 | FLOWABLE MATRIX COMPOSITIONS AND METHODS - Flowable matrix compositions and methods of their use and manufacture are provided. Exemplary compositions may include a flowable, syringeable, putty-like form of acellular human dermal matrix. In some cases, compositions may include a moldable acellular collagen extracellular matrix. In use, the matrix compositions can be used to fill or treat skin voids, channel wounds, and other soft tissue deficiencies. | 2013-10-31 |
20130287742 | SILK FIBROIN AND POLYETHYLENE GLYCOL-BASED BIOMATERIALS - This invention relates to methods and compositions for preparation of silk-PEGs based biomaterials through crosslinking by chemically reacting active polyethylene glycols (PEGs) possessing different chemical groups (e.g., thiols and maleimides functionalized PEGs) that are additionally stabilized by the beta-sheet formation of silk fibroin. The crosslinked silk-PEGs biomaterials present strong adhesive properties, which are comparable to or better than the current leading PEG-based sealant, depending on the silk concentration in the silk-PEGs biomaterials. In addition, the silk-PEGs based biomaterials are cytocompatible, show decreased swelling behavior and longer degradation times, which make them suitable for hemostatic applications where the current available tissue sealant products can be contraindicated. | 2013-10-31 |
20130287743 | METHOD FOR DIFFERENTIATING HUMAN EMBRYONIC STEM CELLS INTO -CELLS FOR THE TREATMENT OF TYPE I DIABETES - The invention provides inter alia methods for differentiating embryonic stem cells into insulin producing cells, as well as compositions comprising such cells, and therapeutic uses of such compositions. | 2013-10-31 |
20130287744 | Biocomposites And Methods Of Making The Same - In general, the present invention is related to biopolymer and biocomposite materials and structures, and methods of making and using the same. In some embodiments, the present invention is directed to oriented collagen based biocomposite materials and structures, and methods of making. | 2013-10-31 |
20130287745 | COMPOSITIONS AND METHODS TO STIMULATE VASCULAR STRUCTURE FORMATION - Cell based compositions and methods are provided for inducing the formation of vascular structures in a warm blooded vertebrate. In one embodiment the composition comprises purified endothelial progenitor cells and adipose stromal cells and the method of stimulating the formation of vascular structures comprises the steps of implanting the composition in a host organism. | 2013-10-31 |
20130287746 | RADIATION CROSS-LINKED COLLAGEN GEL, AND PREPARATION METHOD AND USAGE METHOD THEREOF - The present invention relates to radiation cross-linked collagen gel, and a preparation method and usage method thereof. To this end, the present invention comprises a cross-linked collagen material made by irradiating liquid collagen with radioactive rays, wherein the concentration of said collagen is specifically 0.1-10% (W/V), and the radiation dose (dose rate×time) is 0.1-40 kGy on the basis of 1 kGy/hr. The present invention configured as above can prepare a formulated collagen gel using a physical cross-linking method instead of a chemical cross-linking method, specifically carries out the formulation by mixing biocompatible materials, and provides a method capable of using a cross-linked collagen hydrogel in wound dressings, graft materials, cell cultures and the like. Therefore, the present invention provides an industrially convenient and safe preparation method, thereby instilling a good image to a customer by greatly improving the quality and confidence in the products. | 2013-10-31 |
20130287747 | Methods of Treating Acute Kidney Injury Using Mesenchymal Stem Cells - The invention relates to methods of treating acute kidney injury (AKI) in a patient by administering a therapeutic amount of mesenchymal stem cells (MSC) to a patient in need thereof. Administration of MSCs ameliorates AKI in the patient when administered up to at least 48 hours following kidney injury or decline in kidney function. | 2013-10-31 |
20130287748 | Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. | 2013-10-31 |
20130287749 | FORMULATION FOR SNAIL BAITS COMPRISING ORGANOPHOSPHONIC ACIDS, METAL SALTS AND METHIOCARB - The present invention relates to novel phosphonic acid formulations and to their use as slug and snail baits, and to the corresponding slug and snail baits, to a process for their preparation and to their use for controlling slugs and snails. | 2013-10-31 |
20130287750 | METHOD OF SELECTING STEM CELLS AND USES THEREOF - A method of selecting stem cells from a heterogeneous population of cells is disclosed. The method comprises contacting the population of cells with an apoptosis inducing agent under conditions which are apoptotic to non-stem cells and non-apoptotic to stem cells, thereby selecting the stem cells from the heterogeneous population of cells. The selected stem cells may then be used for a variety of applications including transplantation and differentiation. | 2013-10-31 |
20130287751 | METHOD FOR DEVELOPING NATURAL KILLER CELLS FROM STEM CELLS - A method for producing NK cells from pluripotent stem cells, which includes culturing pluripotent stem cells in a first serum-free medium, aggregating the undifferentiated stem cells to form embryoid bodies, which are cultured to produce hematopoietic precursor cells, and culturing the precursor cells in a serum-free medium to produce the NK cells. Methods for using such NK cells, e.g., in the treatment of cancer and infectious disease are also provided. | 2013-10-31 |
20130287752 | UNIVERSAL ANTI-TAG CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AND METHODS OF TREATING CANCER - The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αFITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of αFITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer. | 2013-10-31 |
20130287753 | Compositions and Methods for Cartilage Repair - Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies. | 2013-10-31 |
20130287754 | ANTIMICROBIAL ANGIOGENIN COMPLEXES (ANGex) AND USES THEREOF - Antimicrobial compositions based upon stabilized angiogenin compositions also contain osteopontin and antimicrobial proteins such as lactoperoxidase (LPO), myeloperoxidase (MPO), salivary peroxidase (SPO) and lysozyme. | 2013-10-31 |
20130287755 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ALANYL-TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-10-31 |
20130287756 | COMPOSITION AND METHOD TO ALLEVIATE JOINT PAIN - Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found with krill oil and/or marine oil in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form. | 2013-10-31 |
20130287757 | COMPOSITION FOR THE REGENERATION OF ATROPHIC TISSUES - An effective composition is for the therapeutic or cosmetic treatment of atrophic cutaneous and subcutaneous tissues, skin appendages, connective tissues or mucous tissues. The composition includes a combination of a salt of adamantane carboxylic acid, preferably salified with an aromatic and/or adamantane base, with a proteolytic enzyme and/or willow extract, salicylic acid, acetylsalicylic acid, salicylate, or acetylsalicylate. Further active ingredients that are suitable for inclusion in the composition are zinc oxide, vitamins, phytoextracts, sugars, amino acids, minerals, further salts, phytoextracts, ventilated green clay and any combination thereof. The composition has a particular synergy between the constituent elements, and is particularly effective in the treatment of atrophic ulcers or bedsores. | 2013-10-31 |
20130287758 | Injectable Amino-Acid Composition - An injectable amino-acid composition acts naturally to fuel collagen synthesis, which retards aging and helps to clear cellular decay while accelerating the cell division that promotes healthy, younger looking skin. The amino-acid composition includes carnosine. The composition is injected into the dermis of patients. The composition can be used in conjunction with botulinum toxin and fillers to enhance their effectiveness and extend their usefulness. | 2013-10-31 |
20130287759 | COLLAGENASE G AND COLLAGENASE H COMPOSITIONS FOR THE TREATMENT OF DISEASES INVOLVING ALTERATIONS OF COLLAGEN - Compositions comprising collagenase G and collagenase H (in a ratio between 1:2.5 and 1:3.5), optionally formulated in hydrogels, and its uses as medicament for the treatment of diseases involving alterations of collagen, such as fibromatosis, palmar Dupuytren's contracture, La Peyronie's disease, Ledderhose's disease or retractable scars. | 2013-10-31 |
20130287760 | TREATMENT FOR DUPUYTREN'S DISEASE - Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-α antagonist. TNF-α antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such ascollagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence. | 2013-10-31 |
20130287761 | COMPOSITION FOR PREVENTING OR TREATING LIVER TOXICITY COMPRISING GALGEUNTANG OR LACTIC ACID BACTERIA FERMENTED GALGEUNTANG - The present invention relates to lactic acid fermented Galgeuntang, and a composition comprising the said lactic acid bacteria fermented Galgeuntang or Galgeuntang as an active ingredient, more particularly, to lactic acid fermented Galgeuntang prepared by the steps of inoculating lactic acid bacteria to Galgeuntang, culturing thereof, and fermenting thereof, and a composition for preventing or treating liver toxicity comprising the said fermented Galgeuntang or Galgeuntang. The composition of the present invention has treatment effect on liver toxicity, so that it can be effectively used as a liver function recovering agent or health food for liver function recovery. | 2013-10-31 |
20130287762 | NEUTRALIZING ANTIBODIES AGAINST GDF-8 AND USES THEREFOR - The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism. | 2013-10-31 |
20130287763 | COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR - The present invention relates to a method of treating cancer by administering an IGF-1R specific antibody in combination with an anti-cancer agent exemplified by an Akt pathway inhibitor. The first and second amounts together comprise a therapeutically effective amount. | 2013-10-31 |
20130287764 | METHOD FOR INHIBITING BONE RESORPTION - The invention is directed to a method of inhibiting bone resorption. The method comprises administering to a human an amount of sclerostin inhibitor that reduces a bone resorption marker level for at least 2 weeks. The invention also provides a method of monitoring anti-sclerostin therapy comprising measuring one or more bone resorption marker levels, administering a sclerostin binding agent, then measuring the bone resorption marker levels. Also provided is a method of increasing bone mineral density; a method of ameliorating the effects of an osteoclast-related disorder; a method of treating a bone-related disorder by maintaining bone density; and a method of treating a bone-related disorder in a human suffering from or at risk of hypocalcemia or hypercalcemia, a human in which treatment with a parathyroid hormone or analog thereof is contraindicated, or a human in which treatment with a bisphosphonate is contraindicated. | 2013-10-31 |
20130287765 | FSH AND FSH RECEPTOR MODULATOR COMPOSITIONS AND METHODS FOR INHIBITING OSTEOCLASTIC BONE RESORPTION AND BONE LOSS IN OSTEOPOROSIS - The invention discloses compositions and methods for decreasing osteoclast which are useful for the treatment of a variety of bone loss disorders. | 2013-10-31 |
20130287766 | ANTIBODIES AND METHODS FOR MAKING AND USING THEM - The invention provides antibodies, including chimeric human antibodies, recombinant antibodies, synthetic anti-bodies, and the nucleic acids encoding them, and methods for making and using these immunoglobulins. The invention provides recombinant and synthetic polypeptide and nucleic acid embodiments of these polypeptides and/or antibodies. The invention also provides polypeptides comprising, or consisting of, consensus human framework regions, or “Independently Consensused Frameworks (ICFs)”, nucleic acids encoding them, and libraries and kits comprising these ICFs and/or antibodies of the invention, individually and in combinatorial libraries and combinations. | 2013-10-31 |
20130287767 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF - The invention discloses 4-(arylamino)selenophenopyrimidine derivatives of formula (I), hydrates, solvates, isomers, or pharmaceutically acceptable salts thereof; process for their preparation and methods of treating or inhibiting or controlling a cell proliferative disorders, particularly cancer using said compounds. Pharmaceutical compositions comprising 4-(arylamino)selenophenopyrimidine derivatives of formula (I) are useful for the treatment, inhibition, or control of cancer. | 2013-10-31 |
20130287768 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY COMPOSITION WHICH SPECIFICALLY BINDS TO CCR4 - A pharmaceutical composition, comprising an antibody composition which specifically binds to human CC chemokine receptor 4 (hereinafter also referred to as CCR4) and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament are required. The present invention can provide a pharmaceutical composition comprising a recombinant antibody against CCR4 and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament. | 2013-10-31 |
20130287769 | TREATMENT OF SOLID TUMORS WITH RAPAMYCIN DERIVATIVES - The present invention is directed to the use of rapamycin derivatives for use in treating solid tumors, optionally in combination with a chemotherapeutic agent. | 2013-10-31 |
20130287770 | HUMAN ANTI-KIR ANITBODIES - Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects. | 2013-10-31 |
20130287771 | Isolation and Purification of Anti-IL-13 Antibodies Using Protein A Affinity Chromatography - Disclosed herein are methods for the isolation and purification of anti-IL-13 antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography (e.g., Protein A affinity chromatography), ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention. | 2013-10-31 |
20130287772 | BIOMARKERS FOR THERANOSTICS - Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA. | 2013-10-31 |
20130287773 | Methods and Compositions for Increasing Arylsulfatase A Activity in the CNS - Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A. | 2013-10-31 |
20130287774 | Prevention of Adverse Effects Caused by CD3 Specific Binding Domains - The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed. | 2013-10-31 |
20130287775 | COMBINATION THERAPY FOR TREATMENT OF IMMUNE DISORDERS - Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders. | 2013-10-31 |
20130287776 | ANTI-FGFR3 ANTIBODIES AND METHODS USING SAME - The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies. | 2013-10-31 |
20130287777 | ST2L Antagonists and Methods of Use - The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing. | 2013-10-31 |
20130287778 | MEANS AND METHODS FOR TREATING DLBCL - The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19×CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, “BiTE”) is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient. | 2013-10-31 |
20130287779 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 2013-10-31 |
20130287780 | PRODUCTS AND METHODS TO PREVENT INFECTIONS - The present invention relates to products and methods for preventing, ameliorating and/or treating infections and other diseases. In one aspect, the products of the present invention relates to compositions comprising germ free colostrum. In another aspect, the products of the present invention relates to compositions comprising synthetically multimerised immunoglobulins. In a third aspect, the products of the present invention relates to compositions comprising germ free colostrum enriched with synthetically multimerised immunoglobulins. The invention also relates to use of said compostions as a pharmaceutical e.g. for prophylactic or ameliorating treatment of infections and other diseases. In addition the invention comprises methods for production of said compositions. | 2013-10-31 |
20130287781 | IMMUNOGLOBULINS - The present invention relates to antibodies to NOGO, pharmaceutical formulations containing such antibodies and the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorder. | 2013-10-31 |
20130287782 | ENTEROCOCCUS ANTIGENS - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 2013-10-31 |
20130287783 | ANTI-GCC ANTIBODY MOLECULES AND METHODS FOR USE OF SAME - Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein. | 2013-10-31 |
20130287784 | Compositions Targeting the Soluble Extracellular Domain of E-Cadherin and Related Methods for Cancer Therapy - The present invention is based, in part, on our discovery that targeting epitopes within one or more of the EC2-EC5 subdomains of E-cadherin results in the death of epithelial-derived tumor cells but not in the death of normal, healthy epithelial cells or non-epithelial cells including endothelial cells and fibroblasts. Accordingly, the compositions of the invention include poly-peptides having an amino acid sequence of one or more of the EC2-EC5 subdomains of E-cadherin and biologically active variants thereof; expression vectors and cells for expressing such polypeptides; and agents (e.g., antibodies) that target the EC2-EC5 subdomains. The methods of the invention include methods of identifying and producing polypeptides having an amino acid sequence of one or more of the EC2-EC5 subdomains of E-cadherin or a biologically active variant thereof; methods of generating agents, such as antibodies, that target these polypeptides; and methods of administering such agents or eliciting their production in vivo to treat epithelial cancers or reduce the risk of their occurrence or recurrence. | 2013-10-31 |
20130287785 | GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7P15-21 AND USES THEREOF - The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance. | 2013-10-31 |
20130287786 | CANINE BABESIOSIS VACCINE ANTIGEN - The present invention relates to the field of veterinary parasitology, especially of canine Babesiosis. In particular the invention relates to a polypeptide being a novel canine | 2013-10-31 |
20130287787 | MONOCLONAL ANTIBODIES THAT REACT WITH THE CAPSULE OF BACILLUS ANTHRACIS - The present disclosure relates to monoclonal antibodies that bind poly-γ-D-glutamic acid (γDPGA), which is present on the surface of | 2013-10-31 |
20130287788 | Treatment of Psychiatric Conditions - The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α. Anxiety and other psychiatric conditions are also improved with this treatment. | 2013-10-31 |
20130287789 | Organic Compounds - The present invention provides a compound of formula I: | 2013-10-31 |
20130287790 | USE OF JAM-A IN DIAGNOSING AND TREATING LEUKEMIA - Methods, compositions, and kits are provided for the use of JAM-A in diagnosing and treating leukemia. These methods, compositions, and kits find many uses, for example in diagnosing an individual with a leukemia, classifying a leukemia, providing a prognosis to an individual with a leukemia, treating an individual with a leukemia, screening candidate agents for the ability to treat a leukemia, and in basic research to better understand the molecular and cellular basis of leukemia. | 2013-10-31 |